Breaking News

WuXi PharmaTech Acquires Abgent

Brings new product lines of research reagents for drug discovery

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi PharmaTech (Cayman) Inc. has acquired Abgent, Inc., a provider of biological research reagent products and services. The financial terms of the acquisition were not disclosed. Dr. Chun Wu, founder and chief executive officer of Abgent, will continue to run the Abgent business unit as vice president of Biological Reagent Products and Services.   Abgent is among the largest manufacturers of antibody reagents for research use. The company has a catalog of approximately 20,000 antibody products...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters